Ember Therapeutics to Present at Marcum MicroCap Conference
NEW YORK, May 31, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based biopharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, today announced that the Company is scheduled to present at the 2016 Marcum MicroCap Conference being held June 1-2, 2016 in New York, NY.
Details of the presentation are as follows:
| Conference: | 2016 Marcum MicroCap Conference |
| Date: | Wednesday, June 1, 2016 |
| Time: | 4:00 p.m. EDT |
| Location: | Grand Hyatt New York, Broadway Room |
About Ember Therapeutics, Inc.
Ember Therapeutics, Inc. is a clinical stage biopharmaceutical company whose primary focus is on utilizing Bone Morphogenetic Protein-7 to catalyze cartilage regeneration for disease modification of Osteoarthritis (OA) and the inhibition and reversal of organ fibrosis in diseases such as Chronic Kidney Disease (CKD) and Alport Syndrome. In particular, Ember has acquired over 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and cGMP manufactured material from Stryker Corporation. For more information, please visit www.embertx.com.
Contact The Ruth Group Lee Roth (investors) (646) 536-7012 lroth@theruthgroup.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
